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Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33 S19Conﬁrmation of diagnosis in LAD-I requires demonstration of absence of
CD18 and associated alpha subunit of CD11a, CD11b, CD11c on ﬂow
cytometry. 4 of 6 patients had complete absence of the integrins. Differ-
ential diagnosis include Interleukin-1 receptor associated kinase deﬁ-
ciency, Hyper IgE syndrome and leukemoid reaction. The only corrective
treatment is hematopoietic stem cell transplantation. Reported survival in
a largest series is5 years after follow up was 75%. These patients die in
childhood if transplantation is not done and if the transplantation is car-
ried out before serious infections, the prognosis is very good.
LAD is a rare form of congenital immune deﬁciency to be suspected in a
child with delayed fall of umbilical cord, highWBC count with neutrophilia
and consanguineous marriage. High index of suspicion and early diagnosis
before infection sets in is important as mortality rate is high. Pseudomonas
was most common organism isolated in the present study.Figure 1. No correlation between serum ferritin and cardiac ironload.ĂRBC Disorders
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Background: Acquired aplastic anemia (AA) is a haematological emer-
gency in children and we have gained enormous knowledge about the
pathogenesis and immune mediated self-destruction of stem cells and
immunosuppressive therapy. Due to its rarity, we have limited data of this
entity, especially, its course and outcome in resource limited countries.
Patients and methods: The case records of children who had been diag-
nosed to have AA since 2002 at our centre were reviewed. The diagnosis of
AA was made in children with pancytopenia without organomegaly and
conﬁrmed by hypocellular bone marrow showing decreased expression of
all three hematopoietic lineages. Clinical ﬁndings including dysmorphism,
thumb abnormalities, congenital malformations and skin hyperpigmen-
tation were noted down. Mitomycin C induced chromosomal instability to
rule out Fanconi anaemia, Ham's test to look for paroxysmal nocturnal
haemoglobinuria and chromosomal analysis to look for complex karyo-
typic abnormalities seen in myelodysplastic syndrome were documented
in all patients.
After initial stabilization, the option of haematopoietic stem cell trans-
plantation (HSCT) was offered to all those who had matched related do-
nors. If not, immunosuppressive therapy was delivered within twomonths
from diagnosis after the child was infection free. A combination of 40mg/
kg/day of Horse derived antithymocyte globulin (ATGAM) and methyl-
prednisolone at 2 mg/kg/day were started for the ﬁrst 4 days through a
central venous catheter. Oral cyclosporine and G-CSF were started on the
ﬁfth day and since 2015 Eltrombopag was added to the IST regimen.
Revolade and GCSF were continued for about 8 to 12 weeks and cyclo-
sporine from 6 to 12 months. All patient received Voriconazole and
Acyclovir prophylaxis till neutrophil recovery to 1000.
Results: A total of 109 children had been diagnosed as AA, of whom, 42
had acquired AA. Themean age of childrenwith acquired AAwas 8.16 years
(2-15 yrs). Boys were twice more commonly affected (ratio M: F ¼ 2:1).
Details are listed in table 1.
Of the 41, 21 underwent HSCT as they had fully matched related donor and
20 children received IST. Of the 20 children who received ATG, 10 children
(70%) had complete remission in a median duration of 78 days. Two of the
three non responderswere treated with second IST and all three succumbed
to the illness. One child developed acute myeloid leukaemia after achieving
partial remission and was salvaged with HSCT, and 1 more non responder
had an unrelated HSCT and is doing well. One child has suffered a relapse
after a durable remission of over 18 months off immunosuppression. The 21
children who have been transplanted have an overall survival rate of 77 %.
Conclusion: Immunosuppressive regimen including Horse ATGAM,
Methyl prednisolone, Cyclosporine, GCSF and Eltrombopag along with
adequate and meticulous supportive care including neutropenic care,
prompt infection management and the use of irradiated and leukode-
pleted blood products results in a 70% response rate and should be offered
to all children with aplastic anaemia with no matched family donor. Theaddition of Elthrombopag has resulted in early recovery of all three cell
lines and must be added to the IST protocol in children.
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Introduction: Advances in blood banking has ensured optimal delivery of
monthly transfusion needed to save the lives of about 10,000 new thal-
assaemia children born each year in our country. The burden of iron che-
lation has now increased as these children survive into their second and
third decade of life. Cardiac failure secondary to myocardial haemoside-
rosis is the most common cause of mortality in these patients. Our study
has been done to evaluate the prevalence and severity of cardiac ironload
in children with beta thalassemia major and the effectiveness of serum
ferritin as a marker of iron overload.
Patients and Methods: We conducted a prospective study from the year
2015-2016 where we performed T2* cardiac magnetic resonance (CMR),
serum ferritin levels and pulmonary artery pressures by echocardiography
in 100 patients with transfusion dependent beta thalassaemia major. The
study had been approved by IRB at the VHS centre and informed consent
was obtained from all of these families. The median age of our patients was
14 (range 7 TO 33 years) with 51% of them being female. The mean serum
ferritin level was 2520.78 +-223.454 ng/ml. High iron overload with a
serum ferritin of over 2500 was seen in 37% of our patients. The 29% pa-
tient group that had less than 1000 ferritin were considered to be chelated
optimally as per international guidelines. A cardiac T2*of over 20 milli-
seconds was taken as a marker of heart free of iron overload.
The mean cardiac MRI T2* was 12.73 +-2.436 milliseconds. About 70% of
our patients had moderate myocardial iron overload (T2* 10-20 ms) and
24% had severe iron overload (T2* <10ms). The mean pulmonary arterial
pressure was 35.96+-8.3 mm of Hg. About 76% of the patients were on a
single drug chelation therapy at the time of evaluation. Following the
cardiac iron status they have been started on combination chelation
therapy consisting of deferasirox and deferiprone.
We found no signiﬁcant correlation (r¼0.014, p¼0.23) between the serum
ferritin levels and myocardial ironload. The most signiﬁcant ﬁnding was
that 38 % (11/29) of our patients with serum ferritin < 1000 had severe
cardiac iron load. A signiﬁcant correlation could also be established be-
tween pulmonary arterial pressures and cardiac MRI T2 *(r¼1.2, p
¼0.0024).
Figure. Signiﬁcant correlation between pulmonary artery pressure and cardiac iron.Ă
Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33S20Conclusion: All patients with transfusion dependent thalassaemia major
should be screened with a cardiac MRI for iron overload from the age of 7
years as serum ferritin done serially alone does not detect tissue iron
deposition. Aggressive chelation with the addition of deferiprone which
acts synergistically with deferasirox or desferrioxamine must be
commenced to reduce the incidence of cardiomyopathy in these patients
despite a low serum ferritin value. This is the ﬁrst comprehensive study of
cardiac iron in India and we plan to follow up this cohort annually to
evaluate the outcome of the intervention with serial cardiac MRI.
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Background: Pancytopenia is a disorder in which all three major formed
elements of blood (red blood cells, white blood cells and platelets) are
decreased in number.Relevance of the study lies in the timely interven-
tion for the causes of pancytopenia which can either bring about a
complete cure or at least a remission from the disease entity. In India not
many studies have been done on this topic especially in pediatric age
group so the present study has been undertaken to evaluate the various
causes of pancytopenia, their clinical proﬁle and outcome.
Methods: This was a prospective observational study of 81 patients aged
between 1 month to 15 years admitted to Department of Pediatrics of King
George Medical University, Lucknow during August 2015 to July 2016 with
Hb<10g/dl, TLC<4000/mm3 and platelets<1 lakh/mm3. Patients under-
going/already undergone chemotherapy and radiotherapy were exclu-
ded.After informed consent, a detailed medical history, physical
examination, complete blood counts, anaemiaworkup, viral markers, bone
marrow examination was done along with transfusion records, treatment
received and outcomes were analysed.
Results: The bulk of patients were from rural background (87%).The mean
age at presentationwas 74months (range 1-180month) withMale:Female
e 2.8:1.
The most common clinical presentations were fever (78%), pallor (67%),
bleeding manifestations (43%); past h/o jaundice (5%) and pesticide
exposure (8%); hepatomegaly (56%) splenomegaly (42%) Lymphadenop-
athy (22%) and knuckle hyperpigmentation (14%).
The haematological parameters showed mean haemoglobin level: 4.9 gm/
dL, WBC: 2676/mm3, ANC: 1009/mm3, platelet: 43700/mm3, MCV:85.5
MCH: 30.5 RDW: 23.5 B12 487.7 Folate 12.3 Ferritin 777 s.Iron 179.8 .PNH
clone was present in 2.1%, Parvo B19 in 6% and EBV in 7% of patients.
5 patients (6%) were lost to follow up or expired before any treatment was
initiated.
Most common causes of pancytopenia found in our study were
Aplastic Anemia (49%), Acute leukemia (27%) and Megaloblastic/Nutritional (18%). Infections (9%) and hypersplenism (6%) etc accounted for
the rest.
All patients with megaloblastic anemia survived despite no trans-
fusions. But patients with very severe Aplastic Anemia and hemato-
logical malignancies had worse outcomes despite ATG courses ;
multiple transfusions and induction chemotherapy respectively.Patient
with Kala Azar, chronic Malaria infections and hypersplenism survived
after appropriate treatment.Also hospital stay was prolonged for leu-
kemias and Aplastic Anemia.
Conclusion: The etiology of pancytopenia varies widely ranging from
transient marrow viral suppression, drugs etc to marrow inﬁltration by
life-threatening malignancy.The severity of pancytopenia and the under-
lying pathology determine the management and prognosis of the patients
.Hence such studies will help in planning the diagnostic and therapeutic
approach in patients with pancytopenia and curtailing delays to reduce
multiple transfusions, pre-treatment infections and overall morbidity and
mortality associated with entity of Pancytopenia.
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Introduction: The Last three decades have witnessed profound changes in
the management of patients with thalassemia major. Regular and periodic
blood transfusion being the main stay of treatment results in iron overload
thus necessitating need for iron chelation. At present three iron chelators
namely, Desferrioxamine, Defriprone and deﬁrasirox are in use alone or in
combinations. Since the iron chelators are required to be given for the life-
time they also cause adverse events which are range from trivial to life
threatening.
Aims: To identify and manage adverse drug events due to iron chelating
drugs experienced by thalassemic patients.
Material and methods: This is an observational study done during 1st
January to 30th June 2016 in Thalassemia Day Care Centre of SMGS hospital,
Govt. Medical College Jammu. All the adverse events were recorded on a
pretestedproformaandwerevalidatedonNaranjo causalityassessmentscale.
Results: Of the 280 patients with the age ranging from 6 months to 53
years registered with Thalassemia Day Care Centre SMGS hospital Govt.
Medical College Jammu only 180 attended regular fortnightly follow up
clinics. Out of these 180 patients 168 are on Iron chelation drugs (129 on
Defriprone, 24 on Deﬁrasirox, 8 on Defriprone + Desferrioxamine, 4 on
Desferrioxamine and 3 on Defriprone + Desferrixamin) Out of 32 events
observed during the course of study 21 (65.62%) were due to Defriprone,
8 (25%) due to Deferasirox and 3 (9.38%) due to Desfferioxamine. Out of
21 events due to Defriprone 12 (57.14%) were gastrointestinal symp-
toms, 5 (23.8%) arthropathy, 2 (9.5%) Neutropenia and 2 (9.5%) throm-
bocytopenia. All 8 (100%) events due to Deferasirox were
gastrointestinal symptoms. 2 (66.66%) events with desferrioxamine
were local reactions and 1 (33.33%) was encephalitis. On Naranjo Cas-
uality scale 5/32 was deﬁnite while as 24 /32 was probable and 3/32
were possible. While 9 were mild reactions, 4 were severe reactions and
19 were moderate reactions.
Conclusion: Majority of adverse events were observed with Defriprone
followed byDeferasirox. Although least adverse eventswere observedwith
desferrioxamine, but adverse events with deferasirox were least severe.
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